Startseite › Chronische lymphatische Leukämie › New York › New York City
Klinische Studien zu Chronische lymphatische Leukämie in New York City, NY
18 Studien zu Chronische lymphatische Leukämie suchen Teilnehmer an Standorten in und um New York City (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Teilnehmer gesuchtPhase 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Teilnehmer gesuchtPhase 3
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Teilnehmer gesuchtPhase 1/2
- Research Site, New York
- Research Site, New York
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Teilnehmer gesuchtPhase 3
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Teilnehmer gesuchtPhase 3
- Columbia University Medical Center, New York
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Teilnehmer gesuchtPhase 3
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Teilnehmer gesuchtPhase 3
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Teilnehmer gesuchtPhase 4
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Teilnehmer gesuchtPhase 3
- David H. Koch Center for Cancer Care, New York
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Teilnehmer gesuchtPhase 1/2
- Research Site, New York
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Teilnehmer gesuchtPhase 1
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Teilnehmer gesuchtPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Teilnehmer gesuchtPhase 3
- Icahn School of Medicine at Mount Sinai /ID# 266328, New York
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Teilnehmer gesuchtPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Teilnehmer gesuchtPhase 4
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Teilnehmer gesuchtPhase 4
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
Teilnehmer gesuchtPhase 1
- Weill Cornell, New York
Chronische lymphatische Leukämie-Studien in anderen Städten
- Boston, MA31 Studien
- Columbus, OH28 Studien
- Durham, NC27 Studien
- Washington, DC22 Studien
- Seattle, WA20 Studien
- Rochester, MN18 Studien
- Houston, TX17 Studien
- Baldwin Park, CA16 Studien
- Milwaukee, WI15 Studien
- Chicago, IL14 Studien
- Cincinnati, OH14 Studien
- Nashville, TN13 Studien
Weitere Studien in New York City
- Brustkrebs136 Studien
- Nichtkleinzelliges Lungenkarzinom121 Studien
- Krebs (alle Arten)109 Studien
- Prostatakrebs103 Studien
- Metastasierender Krebs93 Studien
- Kolorektales Karzinom78 Studien
- Eierstockkrebs69 Studien
- Lungenkrebs60 Studien
- Multiples Myelom60 Studien
- Bauchspeicheldrüsenkrebs60 Studien
- Endometriumkarzinom52 Studien
- Akute myeloische Leukämie51 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.